Pernix Therapeutics (PTX) Misses Q3 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Pernix Therapeutics Reports Third Quarter 2015 Financial Results
November 5, 2015 6:50 AM ESTRevenue Increases 54% Year-Over-Year
Company Reiterates Financial Guidance
MORRISTOWN, N.J., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) (Pernix or the Company), a specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2015. Third Quarter and Recent Business Highlights:
Increased Treximet total prescriptions by 7% and new prescriptions by 13% versus the second quarter of 2015;Increased Silenor total prescriptions by 7%, and new prescriptions by 2% compared to the second quarter of... More